Bolt Biotherapeutics Stock Market Value
| BOLT Stock | USD 0.63 0.01 1.56% |
| Symbol | Bolt |
Bolt Biotherapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bolt Biotherapeutics. If investors know Bolt will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bolt Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.74) | Revenue Per Share 0.294 | Quarterly Revenue Growth (0.11) | Return On Assets (0.29) | Return On Equity (0.58) |
The market value of Bolt Biotherapeutics is measured differently than its book value, which is the value of Bolt that is recorded on the company's balance sheet. Investors also form their own opinion of Bolt Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bolt Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bolt Biotherapeutics' market value can be influenced by many factors that don't directly affect Bolt Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bolt Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bolt Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bolt Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Bolt Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bolt Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bolt Biotherapeutics.
| 10/30/2022 |
| 10/19/2024 |
If you would invest 0.00 in Bolt Biotherapeutics on October 30, 2022 and sell it all today you would earn a total of 0.00 from holding Bolt Biotherapeutics or generate 0.0% return on investment in Bolt Biotherapeutics over 720 days. Bolt Biotherapeutics is related to or competes with KBC Groep, Pfizer, JPMorgan Chase, Davis Select, Frontline, JetBlue Airways, and Merck. Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents... More
Bolt Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bolt Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bolt Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 11.37 | |||
| Value At Risk | (4.05) | |||
| Potential Upside | 3.08 |
Bolt Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bolt Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bolt Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use Bolt Biotherapeutics historical prices to predict the future Bolt Biotherapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.46) | |||
| Treynor Ratio | (0.42) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bolt Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bolt Biotherapeutics Backtested Returns
Bolt Biotherapeutics secures Sharpe Ratio (or Efficiency) of -0.1, which signifies that the company had a -0.1% return per unit of risk over the last 3 months. Bolt Biotherapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Bolt Biotherapeutics' Standard Deviation of 2.05, mean deviation of 1.41, and Risk Adjusted Performance of (0.08) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.55, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bolt Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bolt Biotherapeutics is expected to be smaller as well. At this point, Bolt Biotherapeutics has a negative expected return of -0.21%. Please make sure to confirm Bolt Biotherapeutics' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Bolt Biotherapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.56 |
Modest predictability
Bolt Biotherapeutics has modest predictability. Overlapping area represents the amount of predictability between Bolt Biotherapeutics time series from 30th of October 2022 to 25th of October 2023 and 25th of October 2023 to 19th of October 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bolt Biotherapeutics price movement. The serial correlation of 0.56 indicates that roughly 56.0% of current Bolt Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.56 | |
| Spearman Rank Test | 0.5 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Bolt Biotherapeutics lagged returns against current returns
Autocorrelation, which is Bolt Biotherapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Bolt Biotherapeutics' stock expected returns. We can calculate the autocorrelation of Bolt Biotherapeutics returns to help us make a trade decision. For example, suppose you find that Bolt Biotherapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Bolt Biotherapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Bolt Biotherapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Bolt Biotherapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Bolt Biotherapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Bolt Biotherapeutics Lagged Returns
When evaluating Bolt Biotherapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Bolt Biotherapeutics stock have on its future price. Bolt Biotherapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Bolt Biotherapeutics autocorrelation shows the relationship between Bolt Biotherapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Bolt Biotherapeutics.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.